Antimicrobial Spectrum and Potency of Dalbavancin Tested Against Clinical Isolates from Europe and North America (2003): Initial Results from an International Surveillance Protocol

References

• Campoli-Richards DM, Brogden RN, Faulds D. Teicoplanin. A review of its antibacterial activity, pharmacoki-netic properties and therapeutic potential. Drugs 1990; 40: 449–486.
   PubMed Web of Science ®Google Scholar
• Malabarba A, Goldstein BP. Origin, structure and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother 2005; 55 (Suppl S2):ii15-ii-20.
   Google Scholar
• Candiani G, Abbondi M, Borgonovi M, Roman6 G, Parenti F. In vitro and in vivo antibacterial activity of BI397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother 1999; 44: 179–192.
   Google Scholar
• Goldstein EJ, Citron DM, Merriam CV, Warren Y, Tyrrell K, Fernandez HT. In vitro activities of dalbavancin and nine-comparator agents against anaerobic Gram-positive species and corynebacteria. Antimicrob Agents Chemother 2003; 47: 1968–1971.
   PubMed Web of Science ®Google Scholar
• Jones RN, Biedenbach DJ, Johnson DM, Pfaller MA. In vitro evaluation of BI397, a novel glycopeptide antimicrobial agent. J Chemother 2001; 13: 244–254.
   PubMed Web of Science ®Google Scholar
• Lopez S, Hackbarth C, Romano G, Trias J, Jabes D, Goldstein BP. In vitro antistaphylococcal activity of dalba-vancin, a novel glycopeptide. J Antimicrob Chemother 2005; 55 (Suppl S2):ii21-ii-24.
   Google Scholar
• Mushtaq S, Warner M, Johnson AP, Livermore DM. Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods. J Antimicrob Chemother 2004; 54: 617–620.
   PubMed Web of Science ®Google Scholar
• Lin G, Credito K, Ednie LM, Appelbaum PC. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother 2005; 49: 770–772.
   PubMed Web of Science ®Google Scholar
• Gales AC, Sader HS, Jones RN. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centers. Clin Microbiol Infect 2005; 11: 95–100.
   PubMed Web of Science ®Google Scholar
• Streit JM, Fritsche TR, Sader HS, Jones RN. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis 2004; 48: 137–143.
   PubMed Web of Science ®Google Scholar
• Buckwalter M, Dowell JA. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharm 2005; (in press).
   Google Scholar
• Dorr MB, Jabes D, Cavaleri M, et al. Human pharma-cokinetics and rationale for once-weekly dosing of dalba-vancin, a semi-synthetic glycopeptide. J Antimicrob Chemother 2005; 55 (Suppl S2):ii-25-ii-30.
   Google Scholar
• Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics and pharmacodynamics of intravenous dal-bavancin in healthy volunteers. Antimicrob Agents Chemother 2004; 48: 940–945.
   PubMed Web of Science ®Google Scholar
• Cavaleri M, Riva S, Valagussa A, et al. Pharmacokinetics and excretion of dalbavancin in the rat. J Antimicrob Chemother 2005; 55 (Suppl S2):ii31-ii35.
   Google Scholar
• Jabes D, Candiani G, Roman6 G, Brunati C, Riva S, Cavaleri M. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model. Antimicrob Agents Chemother 2004; 48: 1118–1123.
   Google Scholar
• Lefort A, Pavie J, Garry L, Chau F, Fantin B. Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin. Antimicrob Agents Chemother 2004; 48: 1061–1064.
   PubMed Web of Science ®Google Scholar
• Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin in the treatment of catheter-relat-ed bloodstream infections. Clin Infect Dis 2005; 40: 374–380.
   PubMed Web of Science ®Google Scholar
• Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T. Once-weekly dalbavancin versus standard of care antimicrobial regimens for treatment of skin and soft tissue infections. Clin Infect Dis 2003; 37: 1298–1303.
   PubMed Web of Science ®Google Scholar
• Finch RG, Eliopoulos GM. Safety and efficacy of gly-copeptide antibiotics. J Antimicrob Chemother 2005; 55 (Suppl 52): ii5-ii13.
   Google Scholar
• Woodford N. Novel agents for the treatment of resistant Gram-positive infections. Expert Opin Investig Drugs 2003; 12: 117–137.
   PubMed Web of Science ®Google Scholar
• Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348: 1342–1347.
   PubMed Web of Science ®Google Scholar
• Meka VG, Gold HS. Antimicrobial resistance to linezol-id. Clin Infect Dis 2004; 39: 1010–1015.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Document M100-515. Wayne, PA:CLSI, 2005.
   Google Scholar
• National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacte-ria that grow aerobically. Document M7-A6. Wayne, PA:NCCLS, 2003.
   Google Scholar
• Jones RN, Streit JM, Fritsche TR. Validation of com-mercial dry-form broth microdilution panels and test repro-ducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. Intern J Antimicrob Agents 2004; 23: 197–199.
   PubMed Web of Science ®Google Scholar
• Anderegg TR, Biedenbach DJ, Jones RN. The Quality Control Working Group. Initial quality control evaluations for susceptibility testing of dalbavancin (BI397), an investigational glycopeptide with potent Gram-positive activity. J Clin Microbiol 2003; 41: 2795–2796.
   Google Scholar
• Dutka-Malen S, Evers S, Courvalin P. Detection of gly-copeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J Clin Microbiol 1995; 33: 24–27.
   PubMed Web of Science ®Google Scholar